Verge Genomics, A Clinical-Stage, Tech-Enabled Biotechnology Company, Announced That The First Subject Has Been Dosed In A Phase 1 Clinical Trial Of Vrg50635. Vrg50635 Is A Small Molecule Inhibitor Of Pikfyve, A Novel Therapeutic Target For Amyotrophic Lateral Sclerosis (Als) Discovered By Converge, Verge
